Search results
Results from the WOW.Com Content Network
Puma was founded in September 2010 by Alan Auerbach to identify and in-license compounds that were already in clinical development. [2] This was the same business plan Auerbach had followed at Cougar Biotechnology, which he founded in 2003, and through which he in-licensed abiraterone acetate from BTG plc. [2]
Puma became a public company in 1986, [29] and thereafter was listed on the Börse München and Frankfurt Stock Exchange; its first profit since the IPO was registered in 1994. [30] In May 1989, Rudolf's sons Armin and Gerd Dassler sold their 72 percent stake in Puma to Swiss business Cosa Liebermann SA . [ 31 ]
Puma Biotechnology Inc (NASDAQ:PBYI) is down 27% in early trading Wednesday after announcing a disappointing outcome from a meeting with European regulators over its breast cancer drug neratinib.
Puma Biotech (PBYI) incurs wider loss in Q2. Sales of Nerlynx improve from first-quarter levels. Stock rises 23%.
Puma Biotech (PBYI) betters loss estimates in Q3. However, its only marketed drug, Nerlynx, disappoints with low sequential growth and as a result, shares take a hit.
Fossil also makes licensed accessories for brands such as BMW, Puma, Emporio Armani, Michael Kors, DKNY, Diesel, Kate Spade New York, Tory Burch, Chaps, and Armani Exchange. [4] Kosta Kartsotis, brother of Tom Kartsotis and CEO, owns approximately 12.5% of Fossil stock. The company name is the nickname the brothers gave their father. [5]
The stock of Puma SE (OTCPK:PUMSY, 30-year Financials) appears to be significantly overvalued, according to GuruFocus Value calculation.
Puma Biotech (PBYI) out-licenses development and marketing rights to its breast cancer drug Nerlynx to Pierre Fabre in Europe and across some African countries. Shares fall.